Search
Dr Daniel Ajzensztejn

Dr Daniel Ajzensztejn

www.oncologica.co.uk

Clinical oncology 04630364

 

  • Bupa Platinum consultant
  • Fee assured
  • Open Referral network
Overview
Bupa Platinum consultant
Fee assured
Open Referral network

Specialises in

  • Lung
  • Skin

Offers

  • Face-to-face consultations
  • Video and telephone consultations

About me

Dr Daniel Ajzensztejn is a Consultant Clinical Oncologist specialising in the treatment of lung cancers, mesothelioma and skin cancers. He focuses on cutting edge personalised treatments including stereotactic ablative radiotherapy (SABR/SBRT) and immunotherapy.
Dr Ajzensztejn undertook a DPhil (PhD) at Oxford University where his research focused on ways to use the body's own immune system to fight cancer. He continues to be involved in clinical research and is the principle investigator for a number of clinical trials.

He is an NHS consultant at Oxford University Hospitals, and also undertakes an NHS clinic at Milton Keynes University Hospital. He sees private patients at GenesisCare Oxford and Milton Keynes.



Qualifications
FRCR Clinical Oncology � Royal College of Radiologists
DPhil (PhD) � Tumour Immunology � Oxford University
MSc Oncology � Institute of Cancer Research
MRCP � Royal College of Physicians of London
MBBS Medicine � University College London
BSc Pharmacology � University College London

Areas of interest

Lung Cancer, Mesothelioma, Skin Cancer, Skin Cancer Radiotherapy, BCC, SCC, SABR, Immunotherapy

Medical secretaries

About me
My qualifications & training
My private practice
Consultant's practices
Report this page Edit details Print page

The information contained on Finder is submitted by consultants, therapists and healthcare services, and is declared by these third parties to be correct and compliant with the standards and codes of conduct specified by their relevant regulatory body. Bupa cannot guarantee the accuracy of all of the information provided.

You can find out more about the information on Finder and our website terms of use.